Cinacalcet for the treatment of primary hyperparathyroidism.
The objective of this article is to review the literature regarding the treatment of primary hyperparathyroidism (PHPT) with a focus on cinacalcet. A MEDLINE (1965-June 2009) and bibliographic search of the English-language literature was conducted using the search terms cinacalcet, calcimimetics, primary hyperparathyroidism, and treatment. All articles identified in the search were included. Parathyroidectomy is curative for patients with PHPT; however, there are few options for patients who are not surgical candidates, who refuse surgery, or those with refractory PHPT after parathyroidectomy. Possible treatment options include estrogens, raloxifene, bisphosphonates, calcitonin, and cinacalcet. Cinacalcet has been shown to decrease serum calcium and parathyroid hormone serum levels in patients with PHPT. These trials, however, have not studied the effect of cinacalcet on patient-oriented outcomes such as bone mineral density, nephrolithiasis, or other complications of PHPT. Cinacalcet may be considered to reduce serum calcium and parathyroid hormone serum levels in patients with PHPT who cannot or will not undergo surgery and those with refractory PHPT after parathyroidectomy. Because the effects of cinacalcet on bone mineral density are uncertain, more frequent monitoring of bone mineral density may be required along with a medication proven to improve bone mineral density. Future studies should evaluate the effect of cinacalcet on complications of PHPT.
Department of Pharmacy, Akron General Medical Center, Akron, OH 44307, USA. mdillon@agmc.org
Melanie L
ML
Dillon
Lawrence A
LA
Frazee
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D057966:Calcimimetic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use; D000069449:Cinacalcet; D004164:Diphosphonates / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000150:complications / Q000188:drug therapy*; D009281:Naphthalenes / Q000494:pharmacology / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D057966:Calcimimetic Agents; D004164:Diphosphonates; D004967:Estrogens; D009281:Naphthalenes; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D000069449:Cinacalcet